Loading cancer entity…
Loading cancer entity…
Clinical trials
806 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02472678 | Web-based Tailored Information and Support for Patients With a Neuroendocrine Tumor(WIN) | completed | N/A | 91 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT02481804 | Optimal Feeding for NET Patients(DIVIT-pilot) | completed | N/A | 15 | University Medical Center GroningenOTHER | 1 | May 6, 2024 |
| clinicaltrials |
| NCT02507908 | 5-HIAA in Urine Versus 5-HIAA in Plasma Patients With a Serotonin Producing Neuroendocrine Tumor'(5-HIAA) | completed | — | 59 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT02646644 | Heterogeneity of Metastatic Neuroendocrine Tumors as Determined With 18F-dihydroxyphenylalanine-PET /CT, a Retrospective Analysis(HET-NET) | completed | — | 38 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT02815969 | The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors | completed | — | 210 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03143946 | DIVIT Study Diet and Vitamin Supplementation in Patients With a Neuroendocrine Tumor | completed | N/A | 53 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT03870399 | Study of Tamoxifen in Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression(HORMONET) | completed | Phase 2 | 23 | AC Camargo Cancer CenterOTHER | 2 | May 6, 2024 | clinicaltrials |
| NCT05476978 | Artificial Intelligence in EUS for Diagnosing Pancreatic Solid Lesions | completed | — | 130 | Huazhong University of Science and TechnologyOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT01466036 | Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors | completed | Phase 2 | 61 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT03834701 | Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms(RAPNEN) | completed | N/A | 60 | Catholic University of the Sacred HeartOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT01525082 | Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors | completed | Phase 2 | 20 | Shaheen ShaguftaOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06211803 | Clinical Application of the Prototype J-PET Device(JPETClinic) | completed | — | 10 | Jagiellonian UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT03873870 | 68Ga-DOTATATE PET for Management of Neuroendocrine Tumors | completed | N/A | 1,916 | University Health Network, TorontoOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT02399215 | Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | completed | Phase 2 | 32 | Roswell Park Cancer InstituteOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT06155994 | 68Ga-DOTA-MGS5 PET/CT in Patients With Advanced Neuroendocrine Tumours | completed | Phase 1 / Phase 2 | 12 | Medical University InnsbruckOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT03284775 | Intraoperative Ultrasound in Patients Undergoing Transsphenoidal Surgery for Pituitary Adenoma | completed | N/A | 5 | University College, LondonOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT06143605 | Clinical Relevance of the Salvage Treatment for Colorectal Neuroendocrine Tumors | completed | — | 527 | Yanhong DengOTHER | 0 | Nov 22, 2023 | clinicaltrials |
| NCT02264665 | OPALINE : A Study Of Morbidity And Mortality At 2 Years(OPALINE) | completed | — | 144 | PfizerINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06080204 | Real-world Study on Adjuvant Octreotide Therapy in pNETs | completed | N/A | 411 | Changhai HospitalOTHER | 0 | Oct 18, 2023 | clinicaltrials |
| NCT02893930 | Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT05871320 | Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms(TECANT) | completed | Early Phase 1 | 10 | Jagiellonian UniversityOTHER | 3 | Sep 29, 2023 | clinicaltrials |
| NCT06053437 | Prognostic Indicators in Pituitary Adenoma Surgery: a Comprehensive Analysis of Surgical Outcomes and Complications.(Hyp'Op) | completed | — | 211 | Central Hospital, Nancy, FranceOTHER | 1 | Sep 26, 2023 | clinicaltrials |
| NCT01782443 | Ziv-Aflibercept for Advanced Progressive Carcinoid Tumors | completed | Phase 2 | 19 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 14, 2023 | clinicaltrials |
| NCT00427349 | AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors | completed | Phase 2 | 46 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 5, 2023 | clinicaltrials |
| NCT03043664 | Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors(PLANET) | completed | Phase 1 / Phase 2 | 22 | Duke UniversityOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT04385992 | Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET(NeoLuPaNET) | completed | Phase 2 | 31 | IRCCS San RaffaeleOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05171517 | Study on Microflora Characteristics of Pancreatic Solid Lesions Via Endoscopic Ultrasound-guided Fine Needle Aspiration/Biopsy | completed | — | 200 | Peking Union Medical College HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT03136328 | Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan | completed | Phase 3 | 11 | Montefiore Medical CenterOTHER | 0 | May 9, 2023 | clinicaltrials |
| NCT05816720 | Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®) | completed | — | 31 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT04212793 | Detection of PitNET Tissue During TSS Using Bevacizumab-800CW(DEPARTURE) | completed | Phase 1 | 20 | University Medical Center GroningenOTHER | 1 | Apr 14, 2023 | clinicaltrials |
| NCT05800106 | A Bioequivalence Study of Sunitinib Malate Capsules. | completed | Phase 1 | 24 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 10, 2023 | clinicaltrials |
| NCT00442533 | Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors | completed | Phase 2 / Phase 3 | 200 | Radio Isotope Therapy of AmericaOTHER | 1 | Apr 3, 2023 | clinicaltrials |
| NCT02588170 | Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors | completed | Phase 3 | 219 | Hutchison Medipharma LimitedINDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT02589821 | Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors | completed | Phase 3 | 195 | Hutchison Medipharma LimitedINDUSTRY | 1 | Mar 30, 2023 | clinicaltrials |
| NCT01237457 | 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms | completed | Phase 2 | 143 | Ebrahim S DelpassandOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT04922801 | Optimising Molecular Radionuclide Therapy(SELFIE) | completed | — | 50 | King's College LondonOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT01253161 | Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) | completed | Phase 2 | 29 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT03918759 | Diagnostic Accuracy of Preoperative Diagnostic Procedure in the Assessment of Lymph Node Metastases by NF-PanNENs | completed | — | 100 | IRCCS San RaffaeleOTHER | 1 | Mar 1, 2023 | clinicaltrials |
| NCT03273712 | Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) | completed | Phase 2 | 39 | University of IowaOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT04476082 | Nutrition in Gastrointestinal Tumors(NutriGIT) | completed | — | 66 | University Medicine GreifswaldOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT03673943 | Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE | completed | Phase 3 | 63 | Radiomedix, Inc.INDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT04782596 | Transnasal Endoscopic Pituitary Surgery - the Effect of Posterior Nasal Septum Resection on Nasal Functions | completed | N/A | 30 | University Hospital OstravaOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT03079440 | TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors | completed | Phase 2 | 31 | Asan Medical CenterOTHER | 1 | Dec 6, 2022 | clinicaltrials |
| NCT05565066 | A Real-world Comparison of FNB and FNA in IHC-required Lesions. | completed | — | 439 | Huazhong University of Science and TechnologyOTHER | 1 | Dec 1, 2022 | clinicaltrials |
| NCT01842165 | 177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs(LUMEN) | completed | Phase 3 | 37 | Jules Bordet InstituteOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT00396279 | Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone | completed | Phase 2 | 37 | AmgenINDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT03590119 | Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases(LUTIA) | completed | Phase 2 / Phase 3 | 26 | Marnix LamOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT03722511 | Evaluating an Amino Acid Based Medical Food w/ Diarrhea in Carcinoid Syndrome & Other NETs | completed | Phase 2 | 10 | Lowell Anthony, MDOTHER | 1 | Nov 3, 2022 | clinicaltrials |
| NCT02608203 | [68 Ga]-DOTANOC PET/CT in GEP-NETs(GEP-NOC) | completed | Phase 2 / Phase 3 | 18 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT00842348 | Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero- Pancreatic Endocrine Tumour(NET729) | completed | Phase 3 | 89 | IpsenINDUSTRY | 9 | Oct 12, 2022 | clinicaltrials |
Data updated 23 days agoSource updated May 6, 2024source: clinicaltrials